印度人參 Ashwagandha × 憂鬱症
結論：證據支持但有警示
南非醉茄用於憂鬱症的證據明顯薄弱：L1 Examine 在 3 個條件下皆只給 Grade C 且皆為「Small Improvement」，是五個 target conditions 中最弱者；L2 PubMed 雖有 2 篇 SR/MA 顯示 frequentist 正向 SMD，但 Bayesian hierarchical 分析失去顯著、I2=93%、MDD 專屬試驗稀少且多為焦慮族群外推。
C 🟠 C 薄弱證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
南非醉茄用於憂鬱症的證據明顯薄弱：L1 Examine 在 3 個條件下皆只給 Grade C 且皆為「Small Improvement」，是五個 target conditions 中最弱者；L2 PubMed 雖有 2 篇 SR/MA 顯示 frequentist 正向 SMD，但 Bayesian hierarchical 分析失去顯著、I2=93%、MDD 專屬試驗稀少且多為焦慮族群外推。
Mayo Clinic 直接表示「研究不足」，Cleveland/Harvard/APA/ADAA 對憂鬱症皆未表態，NIH ODS evidence map 亦未納入 depression — 整體屬「機轉合理 + 少量低品質人體研究 + 學會普遍未表態」的 Tier C。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.58
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 附警語發布
信心度
84%
證據方向一致性高
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.582
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
- tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
The effect of Withania somnifera (Ashwagandha) on mental health symptoms in individuals with menta
結論：Depression sub-analysis (5 studies) frequentist SMD -1.28 (95% CI -2.40, -0.16) favored ashwagandha, but Bayesian hierarchical SMD -0.95 (95% CrI -1.96, 0.24) was non-significant; I2 = 93%.
前往 PubMed
Effects of Ashwagandha (Withania Somnifera) on stress and anxiety: A systematic review and meta-an
結論：Pooled depression SMD -5.68 (95% CI -8.43, -2.94) favored ashwagandha; very large effect with wide CI suggests heterogeneity / scale-rescaling artifact.
前往 PubMed
A Standardized Withania somnifera Root Extract with Piperine Alleviates Symptoms of Anxiety and De
結論：HDRS depression scores improved significantly vs placebo at days 30, 60, 90; serum serotonin increased in treatment arm and decreased in placebo.
前往 PubMed
Effects of Withania somnifera (Ashwagandha) on Stress and the Stress-Related Neuropsychiatric Diso
結論：WS improved symptoms of depression and insomnia, but fewer studies investigated these applications; no quantitative pooled estimate; calls for further research.
前往 PubMed
Can Traditional Treatment Such as Ashwagandha Be Beneficial in Treating Depression?
結論：Suggests withanolides and alkaloids may act as antidepressants; mechanism unclear; no statistical synthesis.
前往 PubMed
L5a NIH Office of Dietary Supplements
謹慎
ashwagandha extracts may lower stress, anxiety, and cortisol levels 來源↗
L5b Mayo Clinic
未表態
Ashwagandha has not been well studied in depression 來源↗
L5c Cleveland Clinic
未表態
Evidence is unclear about its effects on anxiety. 來源↗
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
PTT/Dcard 多以「抗壓、降皮質醇」框架討論南非醉茄，少有人直接針對憂鬱症使用；Dcard 偏業配，PTT 多單句推薦未深度反饋。
💬社群實感
無共識（憂鬱症情境下討論稀少，多數轉述為壓力／焦慮用途）
破解迷思 社群最常見的 4 個誤解
✓
事實誤把『憂鬱症』當『壓力大』：社群常以抗壓、降皮質醇代稱，與臨床憂鬱症不同
✓
事實誤以為南非醉茄可取代抗憂鬱藥（多數推文最終仍建議就醫）
✓
事實誤以為複方錠（瑪卡＋南非醉茄＋B 群）效果優於單方，實際無證據
✓
事實誤把『印度人參』當人參家族，其實是茄科，與東方人參無關
🩹 社群通報的副作用
- 少數提及腸胃不適
- 晚服影響睡眠（與瑪卡複方時）
- 個體差異大、部分人感覺無效
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- iHerb 進口單方錠（Now Foods、Swanson）
- 武倍對策（複方含南非醉茄＋瑪卡＋B 群）
- Costco 進口複方錠
- Dcard 藥師業配文常見『KSM-66』標準化原料
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 心理治療（CBT／人際治療）
- 抗憂鬱藥物（SSRI 等）
- 規律運動
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-depression-INT-ashwagandha-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "印度人參能改善憂鬱症",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}